Total Payments
$1,530
2024 Payments
$748.23
Companies
15
Transactions
46
Medicare Patients
4,065
Medicare Billing
$744,520

Payment Breakdown by Category

Food & Beverage$1,530 (100.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $1,530 46 100.0%

Top Paying Companies

Company Total Records Latest Year
AstraZeneca Pharmaceuticals LP $497.65 6 $0 (2024)
Bayer Healthcare Pharmaceuticals Inc. $164.22 7 $0 (2024)
Vifor Pharma, Inc. $139.70 5 $0 (2024)
Mallinckrodt LLC $118.88 1 $0 (2017)
Novartis Pharmaceuticals Corporation $113.02 4 $0 (2024)
Otsuka America Pharmaceutical, Inc. $112.55 5 $0 (2024)
Amgen Inc. $78.09 3 $0 (2024)
ABBVIE INC. $68.92 4 $0 (2024)
Ardelyx, Inc. $52.95 2 $0 (2024)
Travere Therapeutics, Inc. $44.04 2 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $748.23 24 AstraZeneca Pharmaceuticals LP ($222.03)
2023 $313.95 8 AstraZeneca Pharmaceuticals LP ($125.00)
2022 $348.75 13 AstraZeneca Pharmaceuticals LP ($150.62)
2017 $118.88 1 Mallinckrodt LLC ($118.88)

All Payment Transactions

46 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
12/17/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $26.81 General
Category: Cardio-renal
12/10/2024 Amgen Inc. TAVNEOS (Drug) Food and Beverage In-kind items and services $32.22 General
Category: Inflammation
12/04/2024 Vifor Pharma, Inc. Veltassa (Drug) Food and Beverage In-kind items and services $31.65 General
Category: Hyperkalemia
11/19/2024 Amgen Inc. KRYSTEXXA (Biological) Food and Beverage In-kind items and services $23.00 General
Category: Inflammation/Rare Disease
10/22/2024 Amgen Inc. KRYSTEXXA (Biological) Food and Beverage In-kind items and services $22.87 General
Category: Inflammation/Rare Disease
10/15/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $26.19 General
Category: Cardio-renal
10/15/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $1.65 General
Category: Cardio-renal
10/01/2024 Ardelyx, Inc. IBSRELA (Drug) Food and Beverage In-kind items and services $23.98 General
Category: GASTROENTEROLOGY
09/24/2024 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $20.43 General
Category: DIABETES
09/23/2024 Takeda Pharmaceuticals U.S.A., Inc. GATTEX (Drug) Food and Beverage In-kind items and services $18.39 General
Category: INTERNAL MEDICINE
09/17/2024 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $26.45 General
08/26/2024 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $20.02 General
Category: DIABETES
08/06/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $33.08 General
Category: Cardio-renal
07/02/2024 Otsuka America Pharmaceutical, Inc. JYNARQUE (Drug) Food and Beverage In-kind items and services $17.22 General
Category: NEPHROLOGY
06/19/2024 AstraZeneca Pharmaceuticals LP FARXIGA (Drug) Food and Beverage In-kind items and services $97.04 General
Category: Cardiovascular and Metabolism
06/05/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $27.84 General
Category: Cardio-renal
05/07/2024 Fresenius USA Marketing, Inc. Velphoro (Drug) Food and Beverage In-kind items and services $23.20 General
Category: Phosphate binder for ESRD
04/17/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $27.19 General
Category: Cardio-renal
04/08/2024 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $28.97 General
03/27/2024 AstraZeneca Pharmaceuticals LP LOKELMA (Drug) Food and Beverage In-kind items and services $124.99 General
Category: Cardiovascular and Metabolism
03/26/2024 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $27.54 General
02/06/2024 Bayer Healthcare Pharmaceuticals Inc. Kerendia (Drug) Food and Beverage In-kind items and services $21.46 General
Category: Cardio-renal
02/01/2024 ABBVIE INC. TEFLARO (Drug), AVYCAZ, DALVANCE Food and Beverage In-kind items and services $17.07 General
Category: ANTI-INFECTIVE
01/24/2024 Ardelyx, Inc. IBSRELA (Drug) Food and Beverage In-kind items and services $28.97 General
Category: GASTROENTEROLOGY
12/12/2023 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $30.06 General

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 7 1,166 2,015 $775,429 $208,973
2022 7 1,073 1,920 $734,107 $198,525
2021 5 1,004 1,913 $691,739 $196,141
2020 8 822 1,389 $532,933 $140,881
Total Patients
4,065
Total Services
7,237
Medicare Billing
$744,520
Procedure Codes
27

All Medicare Procedures & Services

27 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 354 657 $266,742 $72,640 27.2%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 394 807 $217,890 $59,384 27.3%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 287 302 $178,482 $47,782 26.8%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 95 186 $82,212 $20,927 25.5%
99309 Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes Facility 2023 12 38 $13,756 $3,771 27.4%
99291 Critical care, first 30-74 minutes Facility 2023 11 12 $8,820 $2,416 27.4%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 13 13 $7,527 $2,053 27.3%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 473 1,039 $364,689 $100,069 27.4%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 251 259 $176,379 $47,076 26.7%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 225 403 $98,735 $27,129 27.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 86 157 $70,022 $17,689 25.3%
99308 Follow-up nursing facility visit per day, typically 15 minutes Facility 2022 12 36 $8,604 $2,365 27.5%
99220 Initial hospital observation care per day, typically 70 minutes Facility 2022 13 13 $7,956 $2,206 27.7%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 13 13 $7,722 $1,991 25.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 431 953 $321,161 $92,243 28.7%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 213 234 $155,376 $43,459 28.0%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 257 526 $124,662 $35,888 28.8%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 83 180 $79,020 $21,243 26.9%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 20 20 $11,520 $3,308 28.7%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 347 696 $255,432 $67,704 26.5%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 151 154 $110,418 $28,572 25.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 172 290 $73,950 $19,507 26.4%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 79 148 $57,720 $14,526 25.2%
99309 Subsequent nursing facility visit, typically 25 minutes per day Facility 2020 12 37 $11,914 $3,160 26.5%
99204 New patient office or other outpatient visit, typically 45 minutes Office 2020 18 18 $10,674 $2,803 26.3%

About Dr. Catherine Miranda, M.D

Dr. Catherine Miranda, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1497045942.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Catherine Miranda, M.D has received a total of $1,530 in payments from pharmaceutical and medical device companies, with $748.23 received in 2024. These payments were reported across 46 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($1,530).

As a Medicare-enrolled provider, Miranda has provided services to 4,065 Medicare beneficiaries, totaling 7,237 services with total Medicare billing of $744,520. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.

Practice Information

Products in Payments

  • LOKELMA (Drug) $249.99
  • FARXIGA (Drug) $247.66
  • Kerendia (Drug) $164.22
  • Veltassa (Drug) $139.70
  • ACTHAR (Biological) $118.88
  • JYNARQUE (Drug) $112.55
  • IBSRELA (Drug) $52.95
  • KRYSTEXXA (Biological) $45.87
  • JARDIANCE (Drug) $40.45
  • BENLYSTA (Biological) $39.25
  • AVYCAZ (Drug) $34.04
  • TAVNEOS (Drug) $32.22
  • Velphoro (Drug) $23.20
  • INJECTAFER (Drug) $18.50
  • GATTEX (Drug) $18.39
  • DALVANCE (Drug) $17.81
  • TEFLARO (Drug) $17.07

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Stony Brook